Why investors should consider selling AEHR stock on post-earnings rally

Aehr Test Systems AEHR is exploding higher on July 15 after posting blowout Q4 earnings and offering an absolute stunner of a forward guidance.

In fiscal 2027, the company expects its revenue to come in at $140 million, nearly triple the topline figure last year and miles above the consensus set at $85 million only.

However, there’s reason to treat this monumental post-earnings pop as a window to take profit and sell AEHR shares that are currently trading more than 4x above their price at the start of 2026.

Why is Aehr stock rallying on Wednesday?

AEHR stock is ripping higher on Wednesday because the firm’s Q4 release de-risked its backlog.

According to the earnings release, it ended the fourth quarter with nearly $101 million in backlog – which means roughly 72% of its ambitious fiscal 2027 revenue outlook is already booked.

Crucially, a whopping $60.7 million in bookings during Q4 yielded an exciting 3.2x book-to-bill ratio.

Investors are cheering Aehr Test Systems this morning also because of its aggressive diversification away from the sluggish electric vehicle (EV) silicon carbide market.

Non-EV markets – including artificial intelligence (AI) accelerators, silicon photonics, and optical transceivers – now account for an impressive 95% of the company’s recent annual revenue.

Why AEHR shares are worth selling today

Despite fundamental strength, significant risks loom.

At the current price, AEHR shares are trading at an eye-watering 48x sales (P/S) – a multiple typically reserved for high-margin software giants, not cyclical hardware manufacturers.

Compounding this, Aehr Test Systems is technically non-profitable, posting negative earnings per share of 38 cents over the trailing twelve months; paying such a premium for an unprofitable name is inherently risky.

Adding fuel to the bearish thesis, insiders have been aggressively unloading shares – recording 19 sell transactions and no buys over the past three months.

And while many of these sales were tied to tax obligations on vesting shares, the optics are highly bearish and may intensify the selling pressure on AEHR in the back half of 2026.

Technicals warrant taking profit at current levels

Even from a technical perspective, investors should note that Aehr Test Systems challenged its 50-day moving average (MA) today, but failed to sustainably break above the “closely-watched” $95 level.

While the stock’s immense momentum has drawn bulls back into the fold, this rejection at a crucial resistance level suggests the immediate upside may be strictly capped.

Because AEHR shares failed to decisively clear this technical hurdle on Wednesday, the short-term trend remains vulnerable to profit-taking.

Crucially, while the consensus rating on the company remains at “Moderate Buy”, the mean price target of about $71 has already been left far behind, signaling the Street, on average, sees AEHR as overvalued currently.

All in all, Aehr Test Systems’ fundamentals sure are improving, but valuation and technical levels suggest investors could find a better risk-reward elsewhere.